Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 852 participants.
Also called NCT06660719
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 852 participants
- Registry
-
NCT06660719
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06660719. Randomized; triple masking; primary purpose treatment. Start 2025-02-14 (actual); primary completion 2027-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care
- Acronym
- SP-8203-3001
- Condition
- Ischemic Stroke
- Intervention (Drug)
- SP-8203
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Record details
- Record id
cardio:ct-nct06660719- Content hash
777c468295ef5222f689b1e15280dc3e5272325d45861e74258c78a94a50901d